Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role

被引：29

作者：

Capsoni, Franco ^{[1
]}

Longhi, Matteo

Weinstein, Roberto

机构：

[1] Univ Milan, Ist Ortoped Galeazzi IRCCS, Rheumatol Unit, I-20122 Milan, Italy

[2] Univ Milan, Ist Ortoped Galeazzi IRCCS, Dept Odontol, I-20122 Milan, Italy

来源：

ARTHRITIS RESEARCH & THERAPY | 2006年 / 8卷 / 05期

关键词：

D O I：

10.1186/ar2050

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Several recent reports have described osteonecrosis of the jaws (ONJ) associated with the use of bisphosphonates. Rheumatologists treating bone diseases with bisphosphonate need, therefore, to be aware of this potential risk and plan the prophylaxis, early diagnosis and prevention of potential consequences. We review the literature on this newly described complication, with particular focus on systemic and local predisposing pathologies, preventive measures suggested before and during therapy with bisphosphonates, and the most frequent clinical presentation of the oral lesions. The expert panel recommendations for the management of care of patients who develop ONJ are summarized.

引用

页数：6

共 49 条

[1]

*AM DENT ASS COUNC, 2006, J AM DENT ASSOC, V137, P1144

[2]

Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].

Badros, A ;

Weikel, D ;

Salama, A ;

Goloubeva, O ;

Schneider, A ;

Rapoport, A ;

Fenton, R ;

Gahres, N ;

Sausville, E ;

Ord, R ;

Meiller, T .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952

[3]

Jaw osteonecrosis associated with bisphosphonates:: Multiple exposed areas and its relationship to teeth extractions.: Study of 20 cases [J].

Bagan, JV ;

Jimenez, Y ;

Murillo, J ;

Hernandez, S ;

Poveda, R ;

Sanchis, JM ;

Díaz, JM ;

Scully, C .

ORAL ONCOLOGY, 2006, 42 (03) :327-329

[4]

Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases [J].

Bagan, JV ;

Murillo, J ;

Jimenez, Y ;

Poveda, R ;

Milian, MA ;

Sanchis, JM ;

Silvestre, FJ ;

Scully, C .

JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2005, 34 (02) :120-123

[5]

Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal [J].

Bagger, YZ ;

Tankó, LB ;

Alexandersen, P ;

Ravn, P ;

Christiansen, C .

BONE, 2003, 33 (03) :301-307

[6]

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].

Bamias, A ;

Kastritis, E ;

Bamia, C ;

Moulopoulos, LA ;

Melakopoulos, L ;

Bozas, G ;

Koutsoukou, V ;

Gika, D ;

Anagnostopoulos, A ;

Papadimitriou, C ;

Terpos, E ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587

[7]

The Rresearch on Adverse Drug Events and Reports (RADAR) project [J].

Bennett, CL ;

Nebeker, JR ;

Lyons, EA ;

Samore, MH ;

Feldman, MD ;

McKoy, JM ;

Carson, KR ;

Belknap, SM ;

Trifilio, SM ;

Schumock, GT ;

Yarnold, PR ;

Davidson, CJ ;

Evens, AM ;

Kuzel, TM ;

Parada, JP ;

Cournoyer, D ;

West, DP ;

Sartor, O ;

Tallman, MS ;

Raisch, DW .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2131-2140

[8]

American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].

Berenson, JR ;

Hillner, BE ;

Kyle, RA ;

Anderson, K ;

Lipton, A ;

Yee, GC ;

Biermann, JS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736

[9]

Bisphosphonates and avascular necrosis of the jaw: a possible association [J].

Carter, G ;

Goss, AN ;

Doecke, C .

MEDICAL JOURNAL OF AUSTRALIA, 2005, 182 (08) :413-415

[10]

CHENG A, 2005, AUST DENT J S2, V2, P4

← 1 2 3 4 5 →